Gene-Disorder Association · Article
First reported
1996
Supporting publications
26
Manually curatedApproved treatment annotated
Association Review
In brief
The association between CCND1 (Cyclin D1) and Ovarian Cancer is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
8
Compounds
3
Trials
246of 5,283 via CCND1 compounds
Publications
26
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Ovarian Cancer
The disorder
19 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Phenotype
Clinical features
3 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
Request access
06
Population genetics
GWAS signals
2 GWAS phenotypes
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access
07
Interventions
Therapeutics
3 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
08
Human studies
Clinical trials
5,283 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
26 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
10
Provenance
References & sources
17 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access